OmniAb, Inc. (OABI): Total Liabilities

Annual figures by period end, from SEC filings.

$33.89M
As of 2025-12-31
$29.98M
As of 2026-06-30
-24.8%
3-year compound annual growth
$79.84M2021-12-31: $70.16M2022-12-31: $79.84M2023-12-31: $60.64M2024-12-31: $37.94M2025-12-31: $33.89M$33.89M
2021-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$33.89M-10.7%2026-03-04, Balance as of period end
2024-12-31$37.94M-37.4%2026-03-04, Balance as of period end
2023-12-31$60.64M-24.0%2025-03-18, Balance as of period end
2022-12-31$79.84M+13.8%2024-03-25, Balance as of period end
2021-12-31$70.16Mn/a2023-03-30, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
OmniAb, Inc. (OABI)2025-12-31$33.89M-10.7%
Foxo Technologies Inc. (FOXO)2025-12-31$33.50M-8.1%
MaxCyte, Inc. (MXCT)2025-12-31$31.02M-6.6%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$3.68M-5.8%
Absci Corp (ABSI)2025-12-31$26.85M-22.1%
NRC Health (NRC)2025-12-31$120.89M+19.4%
iSpecimen Inc. (ISPC)2025-12-31$6.44M+6.7%
OneMedNet Corp (ONMD)2025-12-31$5.12M-74.0%
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31$1.20M+5.2%

Compare OABI, FOXO, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗